Por: The Boston Globe Business May 03, 2023
Over nearly a half-century, Carl Icahn has shaken up Wall Street as a corporate raider and activist shareholder, making corporate titans bow down to his demands and change their business strategies.But Tuesday, his publicly traded company, Icahn Enterprises, became a target of Hindenburg Research, the short seller firm that has made its name in recent years by taking on Indian tycoon Gautam Adani and Twitter cofounder Jack Dorsey.Hindenburg... + full article
MarketWatch USA Business May 20, 2023
Illumina’s achievement has been to slash the cost of gene sequencing over the past 15 years, fueling an explosion of applications. In mid-2021, CEO Francis deSouza pursued Grail in a diversification move, closing the $7.1 billion deal without waiting for U.S. and European... + más
Biotech company Illumina pushes back against Carl Icahn’s proxy fight over $7.1 billion Grail deal | CNBC
Icahn vs. Illumina: The CEO’s Job—and Icahn’s Reputation—Are on the Line | MarketWatch
Business Insider USA Business May 03, 2023
Jump to 0 An icon in the shape of a person's head and shoulders. It often indicates a user profile. An icon in the shape of a person's head and shoulders. It often indicates a user profile. All Featured About Follow Subscriptions US Markets Loading... H M S In the news... + más
Hindenburg Research blasts Carl Icahn’s hedge fund as ‘Ponzi-like’ in latest short-seller campaign | New York Post
New York Post USA Business May 02, 2023
Billionaire corporate raider Carl Icahn’s hedge fund has allegedly created a “Ponzi-like economic structure” that has falsely inflated the value of his investments, according to bombshell allegations from a prominent short-seller on Tuesday. Hindenburg Research — whose... + más
Activist investor Icahn becomes target of short seller | The Boston Globe
Activist investor Carl Icahn's wealth plunged by $10 billion after a short-seller accused his company of running a 'Ponzi-like' structure | Business Insider
CNBC USA Health March 21, 2023
In this articleCarl IcahnAdam Jeffery CNBC Biotech company pushed back Monday against Carl Icahn's proxy fight over the company's acquisition of cancer test developer Grail, saying the activist investor's board nominees do not add value. The San Diego-based DNA... + más
Carl Icahn claims Illumina directors got extra insurance to close 'disastrous' $7.1 billion Grail deal | CNBC
Icahn proposes three candidates for Illumina’s board — Here’s what could be next in the battle | CNBC
CNBC USA Business March 18, 2023
Business: develops, manufactures and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and Grail. Grail, which was acquired in , is a health-care company focused on early detection of... + más
Business Insider USA Business December 14, 2022
Carl Icahn had a textbook strategy for the Nevada-based energy utility Southwest Gas Holdings. The legendary activist investor purchased almost 5% of the company's shares in late 2021 and publicly , winning four of its 11 board seats, the ouster of its chief executive, and... + más
Carl Icahn says he still thinks we are in a bear market despite Thursday's rally | CNBC
Carl Icahn snaps up shares of canning giant Crown. Here’s how he may build value | CNBC
CNBC USA Business November 11, 2022
Famed investor Carl Icahn said Thursday's relief rally didn't change his negative view on the market, and he believes a recession is still on the horizon.We keep our portfolio hedged, Icahn said on CNBC's Thursday. I am still very, quite bearish on what is going... + más
The Rare Treasures Of The Fabergé Workshop At GemGenève | Forbes
About iurex | Privacy Policy | Disclaimer |